Progress in LRRK2-Associated Parkinson’s Disease Animal Models

Steven P. Seegobin1,2,3, George R. Heaton1,2,3, Dongxiao Liang1,2,3,4, Insup Choi1,2,3, Marian Blanca Ramirez1,2,3, Beisha Tang4,5 and Zhenyu Yue1,2,3*

1 Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, United States, 2 Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, United States, 3 Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States, 4 Department of Neurology, Xiangya Hospital, Central South University, Hunan, China, 5 National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Hunan, China

Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most frequent cause of familial Parkinson’s disease (PD). Several genetic manipulations of the LRRK2 gene have been developed in animal models such as rodents, Drosophila, Caenorhabditis elegans, and zebrafish. These models can help us further understand the biological function and derive potential pathological mechanisms for LRRK2. Here we discuss common phenotypic themes found in LRRK2-associated PD animal models, highlight several issues that should be addressed in future models, and discuss emerging areas to guide their future development.

Keywords: LRRK2, models, rodent, Drosophila, C. elegans, zebrafish, phenotypes

INTRODUCTION

Parkinson’s disease (PD) is a common, age-dependent, neurodegenerative disease with a lifetime risk of approximately 1.5% (Lees et al., 2009). The defining diagnostic features of PD include bradykinesia, resting tremor, rigidity, cognitive impairment, and psychiatric dysfunction (Goetz et al., 2008). Neuropathologically, PD is characterized by degeneration of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc) and the presence of Lewy Bodies (LBs) throughout the central nervous system (CNS) (Gelb et al., 1999; Dickson et al., 2009). Extensive human genetic studies have led to the discovery of several PD-causing genes, including leucine-rich repeat kinase 2 (LRRK2) (Nalls et al., 2019). PD-causing mutations in LRRK2 occur in up to 41% of select patient populations and, as such, they represent the greatest known cause of heritable PD (Khan et al., 2005; Lesage and Brice, 2009). Mutations in LRRK2 are also found in sporadic PD, occurring at a rate of 1–3% (Gilks et al., 2005; Lesage et al., 2007; Paisán-Ruiz et al., 2008). Importantly, the clinical presentation of Parkinsonism in LRRK2 mutation carriers has been described as indistinguishable from sporadic PD patients (Adams et al., 2005; Kay et al., 2006). Given its importance in both sporadic and familial PD, understanding LRRK2 biology will assist in elucidation of common mechanisms of disease pathogenesis (for a more thorough review, see Kluss et al., 2019).

The LRRK2 gene encodes a large, 2,527-amino acid, 286-kDa, multi-domain protein belonging to the ROCO family (Zimprich et al., 2004). All ROCO proteins are characterized by a GTPase Ras-like G domain (Roc), followed in tandem by a C-terminal of Roc domain (COR) (Bosgraaf and Van Haastert, 2003; Marín, 2006). LRRK2 also contains a serine-threonine kinase domain, capable of phosphorylating both itself and a small group of substrates (West et al., 2005; Sheng et al., 2012; Steger et al., 2016). To date, most of the pathogenic mutations are clustered within the Roc, COR, or kinase domains and are found to alter LRRK2’s biochemical activity (Chen and Wu, 2018).
Although LRRK2 activity has been linked to a diverse range of cellular processes (reviewed by Berwick et al., 2019), a large body of work suggests LRRK2 plays a key role in membrane trafficking along the endo-lysosomal pathway. These functions include synaptic vesicle endocytosis, degradation, and recycling of transmembrane receptors, anterograde trafficking of receptors from the trans-golgi network to lysosomes, and retromer-mediated transmembrane recycling. LRRK2-dependent regulation of these cellular processes may be associated with LRRK2's ability to bind and phosphorylate a cluster of Rab GTPases (Shin et al., 2008; Piccoli et al., 2011; MacLeod et al., 2013; Gómez-Suaga et al., 2014; Schreij et al., 2014; Pan et al., 2017; Steger et al., 2017; Pellegrini et al., 2018; Rivero-Ríos et al., 2019; Sheehan and Yue, 2019).

A diverse range of animal models have been developed which overexpress, knock-out, knock-down, or knock-in mutated and wildtype forms of the LRRK2 gene, for the characterization of LRRK2 biological and pathophysiological functions. In this review, we discuss common phenotypic themes found in LRRK2-associated rodent, Drosophila, Caenorhabditis elegans, and zebrafish animal models and highlight several new avenues toward development of future LRRK2 animal models.

RODENT LRRK2 MODELS

Rodent models have been widely used in the study of LRRK2 biology due to their genetic and neuroanatomical similarities to humans. Both mice and rats possess a mammalian homolog of LRRK2 which shares approximately 86–88% sequence identity to human LRRK2. Importantly, all residues affected by pathogenic mutations in humans are conserved in rodent LRRK2 (Langston et al., 2016). Rodents also possess a LRRK1 homolog, which shares approximately 86–88% sequence identity to human LRRK1, that the resulting phenotypes do not mimic LRRK2-associated PD. Rodents born without LRRK2 exhibit no loss of dopaminergic (DA) neurons, demonstrate mild to no behavioral or locomotor defects, have limited neuropathology, and have unchanged dopamine synthesis (as measured by DOPAC and HVA) (Andres-Mateos et al., 2009; Lin et al., 2009; Tong et al., 2010b; Herzig et al., 2011; Hinkle et al., 2012; Daher et al., 2014).

Although no clear neuronal phenotypes have emerged, several studies have suggested that LRRK2 may fulfill key functions in peripheral tissues. Most notably, LRRK2 KO kidneys exhibit striking age-dependent changes in color and weight, along with ultrastructural abnormalities (Tong et al., 2010a, 2012; Herzig et al., 2011; Hinkle et al., 2012; Baptista et al., 2013). A darker coloration of LRRK2 KO kidneys has been observed as early as 2–3 months, while increases in weight are reported as early as 1–5 months in a sex-specific manner (Herzig et al., 2011; Hinkle et al., 2012; Tong et al., 2012; Ness et al., 2013; Boddu et al., 2015). Curiously, one group has reported a decrease in the weight of LRRK2 KO kidneys at 20–27 months in age (Tong et al., 2010b, 2012). Electron microscopy (EM) analysis of KO kidneys has further revealed an increase in the number and size of lysosomes in epithelial cells of the renal cortex, starting at 4 months of age (Herzig et al., 2011; Hinkle et al., 2012; Tong et al., 2012; Baptista et al., 2013). These studies also found increases in lipid-containing vesicles or droplets and lipofuscin (potentially contained within lysosomes). Alongside ultrastructural abnormalities, multiple groups have reported changes in autophagic markers, LC3, and p62 and lysosomal markers, LAMP-1 and Cathepsin D, consistent with alterations in autophagic markers, LC3, and p62 and lysosomal ultrastructural abnormalities, multiple groups have reported changes in autophagic markers, LC3, and p62 and lysosomal markers, LAMP-1 and Cathepsin D, consistent with alterations in autophagy–lysosomal pathway (Tong et al., 2010a, 2012; Hinkle et al., 2012). Changes in homeostatic parameters regulated by the kidneys have also been reported in LRRK2 KO animals, including increased diastolic blood pressure, decreased plasma and serum chloride, and decreased specific gravity of urine (Herzig et al., 2011; Baptista et al., 2013; Ness et al., 2013; Boddu et al., 2015; Fuji et al., 2015). Kidney dysfunction may be detected using the biomarker of kidney health known as lipocalin-2 (NGAL), which has also been observed to be reduced in plasma and urine (Ness et al., 2013; Fuji et al., 2015).

Several additional abnormalities have been reported in other peripheral organs in LRRK2 KO animals. Lungs of LRRK2 KO rats exhibit an increased number and size of type II alveolar cell lamellar bodies, a lysosome-derived secretory vesicle that stores surfactant (Herzig et al., 2011; Baptista et al., 2013; Miklavc et al., 2014). Indications of liver dysfunction such as increased AST, ALT, and cholesterol levels have also been reported (Ness et al., 2013; Baptista et al., 2013). To a lesser degree, abnormalities in the spleen, such as decreased size and changes in cellular composition, were also found (Ness et al., 2013).

A less-clear phenotype seen has been the disruption of α-synuclein homeostasis in LRRK2 KO rodent models. While several studies have shown that LRRK2 KO or kinase inhibition is protective against α-synuclein aggregation in the brain (Lin et al., 2009; Herzig et al., 2011; Daher et al., 2014; Bae et al., 2018), others have reported that LRRK2 KO causes accumulation of α-synuclein in the kidneys (Tong et al., 2010a, 2012). These seemingly conflicting findings may indicate tissue or model specific differences in α-synuclein metabolism.

An exception to phenotypes seen in single LRRK2 KO models has been a recently developed LRRK1 and LRRK2 double-KO mouse that shows α-synuclein pathology, disruption of the autophagy–lysosomal pathway, and DA neurodegeneration in the CNS (Giaime et al., 2017). While the result suggests the possibility that LRRK1 compensates for the loss of LRRK2 in
### TABLE 1 | Mouse LRRK2 KO models.

| Mouse LRRK2 KO models | Author(s), year(s) | Model | Background (strain) | DA neuronal loss | Locomotor/behavioral changes | Other notes |
|-----------------------|-------------------|-------|---------------------|----------------|-----------------------------|------------|
| 1                     | Giaime et al., 2017 | Double KO of LRRK1 and LRRK2 KO mouse [mouse LRRK2 (−/−)/mouse LRRK1 (−/−)]. Mouse C57BL/6J and 129 hybrid. | Loss at 14–15 months in SNpc and LC. Loss of medium spiny neurons in striatum. | Not assessed. | Presence of synuclein pathology. Increased p62 and LC3 in brain at 15 months. Increased electron dense vacuoles in SNpc at 10 months. |
| 2                     | Dächsel et al., 2010; Hinkle et al., 2012; Volta et al., 2015 | LRRK2 KO by removal of exon 41 of LRRK2 [mouse LRRK2 (−/−)]. C57BL/6J [also contains C57BL/6N – (Yue et al., 2015)] | No loss in SN at 18 months (Hinkle). | Increased thigmotaxis (open field), decreased center exploration time (open field) and decreased object approaches (novel object test) at 7 and 16 months. Increased latency to fall (rotarod) at 7 months (Hinkle). | No synuclein or tau pathology in kidney or brain at 3, 12, and 18 months. Progressive kidney degeneration seen at 3 months with increased lipofuscin or lysosomes. Increased autophagy markers at 20 months (p62 at 12 months) (Hinkle). Increased neurite outgrowth in hippocampal and midbrain neuron cultures (Dächsel). |
| 3                     | Herzig et al., 2011 | LRRK2 KO using cre-recombinase deletion [mouse LRRK2 (−/−)]. C57BL/6J or BALB/c. | Not assessed. | Not assessed. | Darkened kidney. Increased weight and vacuoles at 5 months. Increase of secondary lysosomes in the kidney and lung cells at 1.5 months. Increased diastolic blood pressure. |
| Mouse LRRK2 KO models | Author(s), year(s) | Model | Background (strain) | DA neuronal loss | Locomotor/behavioral changes | Other notes |
|------------------------|-------------------|-------|--------------------|-----------------|-------------------------------|-------------|
| 4 | Tong et al., 2010a, 2012 | LRRK2 KO by deletion of promoter and exon 1 [mouse LRRK2 \((-/-)\)]. | C57BL/6J and 129 hybrid. | No loss up to 24 months. | Not assessed. | Smaller size, increased synuclein aggregation, increased p62, increased LC3-I, decreased LC3-II, and increased apoptosis in the kidneys at 20 months (Tong et al., 2010a). Increased weight (kidney/body weight) and size of kidney at 1, 4, and 7 months. Decreased HMW α-synuclein, decreased LC3-I, and decreased p62 at 7 months. Increased kidney injury molecule-1 and cathepsins (Tong et al., 2012). |
| 5 | Andres-Mateos et al., 2009 | LRRK2 KO by partial deletion of exon 39, complete deletion of exon 40 and insertion of premature stop codon [mouse LRRK2 \((-/-)\)]. | C57BL/6. | No loss in SN up to 18–22 months. | Not assessed. | Lack of sensitivity to MPTP. |
| 6 | Lin et al., 2009; Parisiadou et al., 2009 | LRRK2 KO by deletion of exon 2 resulting in premature stop codon in exon 3 [mouse LRRK2 \((-/-)\)]. | C57BL/6J. | No obvious degeneration (not directly assessed). | No changes in open field and rotarod (Lin). | Protection against α-synuclein aggregation in the striatum (Lin). |
the brain, it raises the question as to whether PD mutations of \textit{LRRK2} could be implicated in the loss of LRRK1/LRRK2 functions. Future studies will have to further verify these findings and elucidate potential mechanisms.

**Rodent Transgenic \textit{LRRK2} Models**

Several rodent transgenic models have been generated to overexpress (OE) WT or pathogenic variants of \textit{LRRK2}. These transgenic models have been developed using either insertions of \textit{LRRK2} cDNA or bacterial artificial chromosomes (BACs) (Tables 3–5).

An emerging theme in transgenic mouse models is that overexpression of pathogenic \textit{LRRK2} mutants, such as G2019S or R1441C, can induce PD-like phenotypes. Reported phenotypes include DA neuronal loss, disruption of dopamine homeostasis, ultrastructural changes, L-DOPA responsive locomotor defects, and pathological accumulations of tau and \textit{α}-synuclein (Ramonet et al., 2011; Chen et al., 2012; Weng et al., 2016; Xiong et al., 2018). Several of these phenotypes have also been reproduced in rats, though without any obvious DA neuronal loss (Zhou et al., 2011; West et al., 2014; Sloan et al., 2016). In mice, DA neuron degeneration is typically observed at mid- to older age, occurring typically at 15–20 months in the SNpc (Ramonet et al., 2011; Weng et al., 2016; Xiong et al., 2018). Prior to cell death, DA neurons are frequently observed to exhibit abnormal morphology and reduced synaptic vesicles (Burke and O’Malley, 2013; Tsika et al., 2014; Liu et al., 2015; Weng et al., 2016). Decreased striatal dopamine content, dopamine metabolites, and evoked dopamine release also frequently occur in conjunction with DA neuronal death (Ramonet et al., 2011; Zhou et al., 2011; Liu et al., 2015; Sloan et al., 2016; Lim et al., 2018; Xiong et al., 2018). Consequently, these rodents exhibit locomotor defects, which are partially rescued with L-DOPA (Sloan et al., 2016; Weng et al., 2016; Xiong et al., 2018). To date, two studies using cDNA \textit{LRRK2}-G2019S overexpression have been able to show both DA neurodegeneration and pathological inclusions (Chen et al., 2012; Xiong et al., 2018). In one such model, phosphorylated tau was increased at 12 months in the SNpc, in parallel with DA neuronal loss (Chen et al., 2012). The other reported an increase in phosphorylated and high molecular weight \textit{α}-synuclein in the striatum and ventral medial body at 24 months of age (Xiong et al., 2018).

Although transgenic OE rodent models can capture many of the cardinal features of PD patients to various extents, there are several key caveats to bear in mind. For example, the question of whether DA neuronal loss occurs in a cell-autonomous or non-cell-autonomous manner has arisen, due to cell type-specific expression. Only mouse models which employ a DA neuron specific (TH) or neuronal transgene (CMV enhancer/PGDF-β) promoter have been able to induce DA neurodegeneration (Ramonet et al., 2011; Chen et al., 2012; Weng et al., 2016; Xiong et al., 2018). Of note, other neuronal transgene promoters, such as Thy1.2 and CaMKII, have failed to induce DA neuronal death, possibly owing to a lack of sufficient expression in midbrain DA neurons (Tsika et al., 2014; Garcia-Miralles et al., 2015). Alternative rodent models generated using a BAC approach, which use endogenous \textit{LRRK2} promoter to drive the expression
| Transgenic overexpression cDNA Mouse Models | Author(s), year(s) | Model (species, gene, WT or mutant, tag) | Background (strain) | Type of expression system | DA neuronal loss | Locomotor/behavioral changes |
|-------------------------------------------|-------------------|-----------------------------------------|--------------------|---------------------------|----------------|-----------------------------|
| 1                                         | Xiong et al., 2018 | Human LRRK2 G2019S – TAP.              | C57BL/6 (backcrossed). | Tet-inducible OE of human LRRK2 G2019S with human TH promoter (catecholaminergic cell specific). | Loss at 15 months in SNpc and 24 months in LC. | Decreased stride length and increased descending time on the pole test at 24 months. Normal rotarod and open field. |
| 2                                         | Xiong et al., 2018 | Human LRRK2 GS/Kinase Dead (G2019S + D1994A) – TAP. | C57BL/6 (backcrossed). | Tet-inducible OE of human LRRK2 kinase dead with human TH promoter (catecholaminergic cell specific). | No loss in SNpc or LC up to 25 months. | No changes on rotarod, open-field, pole test, and gait analysis. |
| 3                                         | Weng et al., 2016  | Human LRRK2 R1441C – HA.               | FVB/N.              | OE of human LRRK2 R1441C under CMVE/PDGF-β promoter (neuronal transgene specific). | Loss in SNpc at 16 months. No neuronal loss in striatum up to 16 months. | Decreased velocity, distance moved and rearings starting at 16 months. |
| 4                                         | Liu et al., 2015   | Human LRRK2 WT – HA.                   | C57BL/6J.           | Tet-inducible OE of human LRRK2 WT with PITX3 promoter (DA midbrain neuron specific). | No loss in SNpc or VTA up to 20 months. | No changes in open field, rotarod, and gait analysis up to 18 months. |
| 5                                         | Liu et al., 2015   | Human LRRK2 G2019S – HA.              | C57BL/6J.           | Tet-inducible OE of human LRRK2 G2019S LRRK2 with PITX3 promoter (DA midbrain neuron specific). | No loss in SNpc or VTA up to 20 months. | No changes in gait analysis, rotarod, fine movement and horizontal/vertical movement. |
| 6 (Garcia-Miralles et al., 2015)           | Note: (Herzig et al., 2012) developed a similar model | Human LRRK2 WT.      | C57BL/6.            | OE of human LRRK2 WT with murine Thy1.2 promoter (neuronal transgene specific). | No loss in SNpc up to 12–13 months (limited expression in SNpc). | Not assessed. |
| 7 (Garcia-Miralles et al., 2015)           | Note: (Herzig et al., 2012) developed a similar model | Human LRRK2 G2019S.  | C57BL/6.            | OE of human LRRK2 G2019S with murine Thy1.2 promoter (neuronal transgene specific). | No loss in SNpc up to 12–13 months (limited expression in SNpc). | Not assessed. |

(Continued)
| Transgenic overexpression cDNA Mouse Models | Author(s), year(s) | Model (species, gene, WT or mutant, tag) | Background (strain) | Type of expression system | DA neuronal loss | Locomotor/behavioral changes |
|-------------------------------------------|--------------------|------------------------------------------|-------------------|---------------------------|----------------|-----------------------------|
| 8 | Tsika et al., 2014 | Human LRRK2 R1441C | C57BL/6J | Conditional (Cre-dependent) OE of human LRRK2 R1441C with murine ROSA26 promoter (crossed with DAT-Cre for central DAT-positive midbrain neuron expression) | No loss in SNpc up to 22 months. | No changes in open field, rotarod or olfactory sense at 19–20 months. |
| 9 | Maekawa et al., 2012 | Human LRRK2 I2020T | C57BL/6J (backcrossed) | OE of human LRRK2 I2020T with CMV promoter (whole body expression). | No loss in SNc up to 18 months. | Increased slips on beam test (23 weeks), decreased latency to fall time (34 weeks), and increased rearing (22 weeks). |
| 10 | Chen et al., 2012; Weng et al., 2016 | Human LRRK2 WT | FVB/N | OE of human LRRK2 WT with CMVE/(PDGF)-β promoter (neuronal transgene specific). | No loss in SNpc. No neuronal loss in striatum, cerebral cortex, or hippocampus. | No changes in open field and pole test. |
| 11 | Chen et al., 2012; Chou et al., 2014 | Human LRRK2 G2019S | FVB/N | OE of human LRRK2 G2019S with CMVE/(PDGF)-β promoter (neuronal transgene specific). | Loss in SNpc starting at 12 months (50%). No neuronal loss seen in striatum, cerebral cortex, or hippocampus (Chen). No loss at 8–9 months in SNpc (Chou). | Decreased ambulatory movement, distance moved, and increased time on pole test at 12 months (Chen). Decreased ambulatory movement at 8–9 months (Chou). |
| 12 | Herzig et al., 2012 | Human LRRK2 WT | C57BL/6 | OE of human LRRK2 WT with murine Thy1 promoter (neuronal transgene specific). | Not assessed (limited expression in SNpc). | Trend for increased rotarod and distance traveled, but not significant (data not shown). |
| 13 | Herzig et al., 2012 | Human LRRK2 G2019S | C57BL/6 | OE of human LRRK2 G2019S with murine Thy1 promoter (neuronal transgene specific). | No obvious pathology up to 19 months due to lack of expression in SN (data not shown). | Increased rotarod performance at 3–4 months and increased distance traveled in first 30 min at 7 months (males only). These effects waned later in age (data not shown for rotarod). |

(Continued)
TABLE 3 | Continued

| Transgenic overexpression cDNA Mouse Models | Author(s), year(s) | Model (species, gene, WT or mutant, tag) | Background (strain) | Type of expression system | DA neuronal loss | Locomotor/behavioral changes |
|-------------------------------------------|-------------------|------------------------------------------|--------------------|---------------------------|-----------------|------------------------------|
| 14                                        | Ramonet et al., 2011 | Human LRRK2 WT.                          | C57BL/6J (backcrossed). | OE of human LRRK2 WT with CMVE/human (PDGF)-β promoter (neuronal transgene specific). | Not assessed (limited expression in SNpc). | Not assessed. |
| 15                                        | Ramonet et al., 2011 | Human LRRK2 R1441C.                      | C57BL/6J (backcrossed). | OE of human LRRK2 R1441C with CMVE/human (PDGF)-β promoter (neuronal transgene specific). | Not assessed (limited expression in SNpc). | Decreased horizontal and vertical activity measured by beam breaks at 15 months. |
| 16                                        | Ramonet et al., 2011; Lim et al., 2018 | Human LRRK2 G2019S.                      | C57BL/6J (backcrossed). | OE of human LRRK2 G2019S with CMVE/human (PDGF)-β promoter (neuronal transgene specific). | Loss in SNpc at 19–20 months (17–18%). No loss in VTA at 19–21 months (Ramonet). | Decreased latency to fall time on rotarod at 65–83 weeks and increased anxiety/depression 43–52 weeks (Lim). |
| 17                                        | Lin et al., 2009    | Human LRRK2 WT – HA.                     | C57BL/6J.            | Tet-inducible OE of human LRRK2 WT with CaMKII promoter (neuron specific). | Not assessed. | No changes in beam breaks and latency to fall up to 6 months (Lin). |
| 18                                        | Wang L. et al., 2008; Lin et al., 2009 | Human LRRK2 G2019S – HA.                | C57BL/6J.            | Tet-inducible OE of human LRRK2 G2019S with CaMKII promoter (neuron specific). | Not assessed in SNpc (limited expression). No neuronal loss in striatum or cortex up to 20 months (Lin). | Increased beam breaks at 12 and 18 months. Rearings normal up to 18 months (Lin). |
| 19                                        | Lin et al., 2009    | Human LRRK2 kinase domain deletion – HA. | C57BL/6J.            | Tet-inducible OE of human LRRK2 kinase domain deletion with CaMKII promoter (neuron specific). | Not assessed. | Not assessed. |
### TABLE 4 | Transgenic OE of LRRK2 using BAC in mouse models.

| Transgenic overexpression BAC mouse models | Author(s), year(s) | Model (species, gene, WT or mutant, tag). | Background (strain). | Type of expression system. | DA neuronal loss. | Locomotor/behavioral changes. |
|------------------------------------------|-------------------|------------------------------------------|---------------------|---------------------------|------------------|-------------------------------|
| 1                                        | Beccano-Kelly et al., 2015; Volta et al., 2015 | Human LRRK2 WT. | C57BL/6J [backcrossed from Melrose et al. (2010) by Beccano-Kelly]. | OE of human LRRK2 WT using BAC (RP-11 568G5). | Not assessed. | Decreased total distance, ambulatory time and rearings at 3–6 months (Beccano-Kelly). Decreased rearings at 12 months (Volta). |
| 2                                        | Volta et al., 2015 | Human LRRK2 G2019S. | C57BL/6J [backcrossed from Melrose et al. (2010)]. | OE of human LRRK2 G2019S using BAC (RP-11 568G5). | Not assessed. | Increased cylinder rearings at 6 months, but normal at 12 months. |
| 3                                        | Dächsel et al., 2010; Melrose et al., 2010 | Human LRRK2 WT. | FVB/N (backcrossed – Melrose). | OE of human LRRK2 WT using BAC (RP-11 568G5). | No loss in SN up to 22–24 months (Melrose). | No changes in open field, beam-crossing test, gait footprint analysis inked footprint analysis or negative geotaxis test at 7–8 months (Melrose). |
| 4                                        | Dächsel et al., 2010; Melrose et al., 2010 | Human LRRK2 G2019S. | FVB/N (backcrossed). | OE of human LRRK2 G2019S using BAC (RP-11 568G5). | No loss in SN up to 22–24 months (Melrose). | Increased mean path length and thigmotaxis (wall hugging) in open field at 7–8 months. No other changes in beam-crossing, gait footprint analysis or negative geotaxis tests (Melrose). |
| 5                                        | Dächsel et al., 2010 | Human LRRK2 Y1699C. | FVB/N (backcrossed). | OE of human LRRK2 Y1699C using BAC (RP-11 568G5). | Not assessed. | Not assessed. |
| 6                                        | Li et al., 2007, 2010 | Mouse LRRK2 WT – FLAG. | C57BL/6J. | OE of mouse LRRK2 WT using BAC (RP23-312I9). | No loss in SNpc at 12 months (2010). | Increased rearings at 6 and 12 months, total distance at 12 months and total move time at 12 months. Decreased slips/step at 12 months (2010). |

(Continued)
### TABLE 4 | Continued

| Author(s), year(s) | Model (species, gene, WT or mutant, tag) | Background (strain) | Type of expression system | Transgenic overexpression BAC | DA neuronal loss | Locomotor/behavioral changes |
|--------------------|------------------------------------------|---------------------|---------------------------|-----------------------------|----------------|-------------------------------|
| 7 Li et al., 2010   | Mouse LRRK2-G2019S–PLAG.                | C57BL/6J            | OE of mouse LRRK2 G2019S with mouse BAC (RP23-312I9) | No loss in SNpc at 12 months. No changes in open field or food intake at 12 months. | No loss in SNpc at 12 months. No changes in open field or food intake at 12 months. | No loss in SNpc at 12 months. No changes in open field or food intake at 12 months. |
| 8 Li et al., 2009   | Human LRRK2 WT                          | FVB/NJ             | OE of human LRRK2 WT with BAC. | No loss up to 9–10 months. | No loss up to 9–10 months. | No loss up to 9–10 months. |
| 9 Li et al., 2009; Bichler et al., 2013; Dranka et al., 2013 | Human LRRK2 R1441G–PLAG. | C57BL/6J | OE of human LRRK2 R1441G with human BAC (RP135). | No loss up to 9–10 months. | No loss up to 9–10 months. | No loss up to 9–10 months. |

has presented with more subtle phenotypes, such as changes in dopamine homeostasis and mild behavioral or locomotor dysfunction (Tables 4, 5).

One clear advantage of rodent OE models is that they have enabled the study of neurodegenerative mechanisms. One potential mechanism of action is LRRK2-mediated phosphorylation of synaptic proteins with known functions in vesicle endocytosis. Specifically, LRRK2 has been shown to phosphorylate the synaptic proteins synaptojanin 1 (SYNJ1), Endophilin A1 (SH3GL2) and auxilin (DNAJC6) (Matta et al., 2012; Arranz et al., 2015; Pan et al., 2017; Nguyen and Krainc, 2018). Broadly speaking, these studies have proposed that increased LRRK2-kinase activity disrupts the physiological function of these presynaptic trafficking proteins, resulting in defects in synaptic vesicle endocytosis (Pan et al., 2019).

### Mouse LRRK2 KI Models

Currently, the disease mutations of LRRK2 knock-in (KI) models have only been developed in mice (Table 6). Unlike OE models, KI models do not suffer from potential overexpression artifacts or interspecies differences. However, LRRK2 KI mouse models have failed to show DA neuron degeneration or α-synuclein pathology. Rather, these models exhibit neurophysiological changes, altered DA homeostasis, and modest behavioral abnormalities.

Two independent groups have reported that the LRRK2-G2019S KI mice exhibit increased frequency of spontaneous excitatory post-synaptic potentials (sEPSCs) in spiny projection neurons (SPNs) of the striatum (Matikainen-Ankney et al., 2016; Volta et al., 2017). Young (1–3 months) G2019S KI mice also exhibit elevated dopamine release upon repeated stimulation (Volta et al., 2017). These changes are mirrored by increases in total distance moved and rearings indicative of hyperkinesia at a young age (Longo et al., 2014; Yue et al., 2015; Volta et al., 2017). However, in older mice (>12 months), extracellular levels of dopamine appear decreased and hyperkinetic behavior is reduced (Yue et al., 2015; Volta et al., 2017). Perhaps surprisingly, a recent study has reported that young G2019S KI mice are more resilient to chronic social defeat stress (CSDS) (Matikainen-Ankney et al., 2018). The authors suggest that this may be due to the inability for calcium-permeable AMPA receptors (CP-AMPARs) to integrate into the synaptic membrane, blocking the formation of long-term potentiation (LTP). However, whether the synaptic changes at young adulthood in rodents confer altered non-motor or motor phenotypes in late-onset PD remains unclear.

### Drosophila LRRK2 MODELS

Drosophila LRRK2 models can offer several advantages over rodents. Firstly, the relatively short lifespan of Drosophila (~2 to 3 months) allows age-dependent changes in phenotypic variability to manifest quicker than in rodent models (e.g., synuclein pathology; Feany and Bender, 2000). In addition, the presence of the UAS-GAL4 system in several Drosophila lines can create a diverse range of genetic manipulations. Finally,
### TABLE 5 | Rat transgenic LRRK2 models.

| Author(s), year(s) | Model (species, gene, mutation, tag) | Background (strain) | Type of expression system | DA neuronal loss | Locomotor/behavioral changes |
|--------------------|--------------------------------------|---------------------|---------------------------|-----------------|-----------------------------|
| **Transgenic overexpression cDNA rat models** | | | | | |
| 1 | Zhou et al., 2009, 2011 | Human LRRK2 WT – HA. | Sprague-Dawley | Tet-inducible OE of human LRRK2 WT with a ubiquitous promoter (TRE-miniCMV). | Not assessed. | Not assessed. |
| 2 | Zhou et al., 2011 | Human LRRK2 G2019S – HA. | Sprague-Dawley | Tet-inducible OE of human LRRK2 G2019S with a ubiquitous promoter (TRE-miniCMV). | No loss in SNpc and LC at 18 months (compared to "tet-only" instead of non-transgenic). | Increased total distance (open field) at 18 months using temporary expression model (given doxycycline until 5 months). |
| **Transgenic overexpression BAC rat models** | | | | | |
| 1 | Sloan et al., 2016 | Human LRRK2 WT – YPet. | Sprague-Dawley | OE of human LRRK2 WT with BAC. | Not assessed. | No changes in rotarod, T-maze, or grip strength test. |
| 2 | Sloan et al., 2016 | Human LRRK2 G2019S – YPet. | Sprague-Dawley | OE of human LRRK2 G2019S with BAC. | No loss in SN at 18–21 months. | Decreased latency to fall at 3–6 and 18–21 months. Decreased alternations in T-maze at 18–21 months. |
| 3 | Sloan et al., 2016 | Human LRRK2 R1441C – Ypet. | Sprague-Dawley | OE of human LRRK2 R1441C with BAC. | No loss in SN at 18–21 months. | Decreased latency to fall, decreased alternations (T-maze) and increased gait disturbances at 18–21 months. |
| 4 | (Shaikh et al., 2015) (Taconic – Dr. Chenjian Li) | Human LRRK2 R1441G. | Sprague-Dawley | OE of human LRRK2 R1441G under BAC. | No loss in SN or striatum up to 9 months. | No changes in forelimb placing test, adjusting steps test, footprint analysis, open field test, acoustic startle response and Morris water maze. |
| 5 | (Walker et al., 2014; West et al., 2014; Daher et al., 2015; Lee et al., 2015; Volpicelli-Daley et al., 2016) (Taconic – Dr. Chenjian Li) | Human LRRK2 G2019S. | Sprague-Dawley | OE of human LRRK2 G2019S under BAC (MJ Farrer Lab). | No changes (Daher). | Decreased latency to fall on rotarod at 6 months. No difference in cylinder and beam walking test (Walker). Postural instability at 8 months but was recovered at 12 months. Rearings increased at 12 months (Lee). |
| Mouse LRRK2 KI models | Author(s), year(s) | Model (species, gene, mutation, tag) | Background (strain) | DA neuronal loss | Locomotor/behavioral changes | Other notes |
|-----------------------|-------------------|--------------------------------------|--------------------|-----------------|-----------------------------|-------------|
| 1                     | Giesert et al., 2017 | Mouse LRRK2 R1441C KI. | C57BL/6J (backcrossed). | No loss in SN up to 28 months. | Increased time on pole test, increased total slips (beam test), and increased time on ladder test at >24 months. Gait analysis shows decreased front paw angle on CatWalk at 26 months. Reduction in odor sensitivity and discrimination at 24–26 months. Decrease in time spent swimming on forced swim test at 8–15 months. Tail suspension test altered at 8 months in females (See Giesert for important negative data). | No synuclein or tau pathology. R1441C KI line has locomotor or behavioral symptoms that may indicate prodromal/early phase of PD in humans. |
| 2                     | (Steger et al., 2016) (Eli Lilly) | Mouse LRRK2 G2019S KI. | C57BL/6J. | Not assessed. | Not assessed. |
| 3                     | (Steger et al., 2016) (Michael J. Fox Foundation) | Mouse LRRK2 A2016T KI (kinase inhibitor resistant). | C57BL/6NJ. | Not assessed. | Not assessed. |
| 4                     | Ito et al., 2016 | Mouse LRRK2 Kinase Dead (D2017A) KI. | C57BL/6J (backcrossed). | Not assessed. | Increased latency to fall at 40 rpm but not 50 rpm on rotarod (Zhou). |
| 5                     | Ito et al., 2016; Zhou et al., 2018 | Mouse LRRK2 [S910A + S935A] KI. | C57BL/6 (backcrossed). | Not assessed. | Reduced astrocytes in dorsolateral striatum at 18 months. Increased α-synuclein in dorsolateral striatum at 3 months. |

(Continued)
| Mouse LRRK2 KI models | Author(s), year(s) | Model (species, gene, mutation, tag) | Background (strain) | DA neuronal loss | Locomotor/behavioral changes | Other notes |
|-----------------------|-------------------|-------------------------------------|--------------------|----------------|-----------------------------|------------|
| 6                     | (Matikainen-Ankney et al., 2016, 2018) (Eli Lilly) | Mouse LRRK2 G2019S KI. | C57BL/6NTac. | Not assessed. | More resistant to chronic social defeat stress (CSDS). Altered self-care based on grooming time. No difference on rotarod or elevated plus maze test (2018). | Increased sEPSC frequency in dorsal striatal SPNs at P21 (restored with kinase inhibition). SPNs at P21 had greater spine head width (2016). Decreased sEPSC amplitude in NAc SPNs. Mice lack CP-AMPA at baseline and post-CSDS. Unable to form LTP in dorsal striatal SPNs (2018). |
| 7                     | (Matikainen-Ankney et al., 2016) (Eli Lilly) | Mouse LRRK2 Kinase Dead (D2017A) KI. | C57BL/6NTac. | Not assessed. | Not assessed. | No synuclein, tau or ubiquitin pathology. Alterations in open field and DA uptake in response to reserpine (depletes DA in striatum). |
| 8                     | Liu et al., 2014 | Mouse LRRK2 R1441G KI. (backcrossed). | C57BL6/N (backcrossed). | No loss in SNpc up to 18–22 months. No TH cell loss in striatum at 18–22 months. | No changes at 3 and 12 months in open field. | Increased distance traveled and latency to fall at 6 months (not seen at 12 months) (Yue). Increased phospho-tau in corpus callosum and midbrain at 18 months. Decrease in extracellular DA at 12 months. Dose dependent increase in kinase activity. Decrease fission/fusion of mitochondria at 15 months (Yue). Increased sEPSC frequency in DIV21 cortical cultures. Reduced synapsin 1 phosphorylation in DIV21 cortical cultures (Beccano-Kelly). Increased sEPSC frequency in striatal SPNs at 1–3 months and increased dopamine transmission (Volta). |
| 9                     | Dächsel et al., 2010; Beccano-Kelly et al., 2014; Yue et al., 2015; Volta et al., 2017 | Mouse LRRK2 G2019S KI. | C57BL/6. | No loss in SN up to 18–20 months (Yue). | Increased distance traveled and latency to fall at 6 months (not seen at 12 months) (Yue). Increased sEPSC frequency in striatal SPNs at 1–3 months and increased dopamine transmission (Volta). | (Continued) |
| Mouse LRRK2 KI models | Author(s), year(s) | Model (species, gene, mutation, tag) | Background (strain) | DA neuronal loss | Locomotor/behavioral changes | Other notes |
|------------------------|-------------------|--------------------------------------|---------------------|-----------------|-----------------------------|-------------|
| 10                     | Herzig et al., 2011; Longo et al., 2014 | Mouse LRRK2 G2019S KI | C57BL/6J or BALB/c. | No loss in striatum at 20 and 22 months (Herzig). | Decreased immobility time (bar time) at 6–19 months. Increased number of steps (drag test) at 6–19 months. Decreased immobility time (open field) at 15 months. Increased total distance traveled (open field) at 15 months (Longo). | No synuclein pathology. Increased diastolic blood pressure (Herzig). |
| 11                     | Herzig et al., 2011; Longo et al., 2014 | Mouse LRRK2 Kinase Dead (D1994S) KI | C57BL/6 or BALB/c. | Not assessed. | No changes in bar test, drag test, rotarod and open field up to 15 months (Longo). | Increased kidney weight at 6 months. Darkened kidney (Herzig). |
| 12                     | Tong et al., 2009; Nichols et al., 2010; Parisiadou et al., 2014 | Mouse LRRK2 R1441C KI | C57BL/6. | No loss in SNpc or LC at 3, 12, and 22 months (Tong). | No changes in open field, rotarod and acoustic startle response. No change in AMPH injection compared (Tong). | Decreased sensitivity for firing by DA (Tong). Excess PKA activity in SPNs (Parisiadou). |
the dopaminergic system in Drosophila consists of six well-defined neuronal clusters that can easily be quantified to assay DA-specific neuronal death.

**Drosophila dLRRK KO Models**

Unlike rodents and humans, which possess both LRRK1 and LRRK2 genes, Drosophila only possesses a single LRRK2 ortholog, dLRRK. dLRRK is 2,445 amino acids in length and shares an overall sequence identity of 24% with human LRRK2 (Wang D. et al., 2008). Like LRRK2 KO rodent models, loss of dLRRK does not cause DA neurodegeneration (Table 7) (Imai et al., 2008; Wang D. et al., 2008; Tain et al., 2009). Several studies have, however, reported locomotor deficits and loss of fertility in dLRRK KOs (Lee et al., 2007; Imai et al., 2008; Tain et al., 2009). An unclear point of investigation is whether dLRRK KOs are sensitive or protective to treatment with reactive oxygen species (ROS) with two studies observing conflicting evidence for H$_2$O$_2$ on mortality (Imai et al., 2008; Wang D. et al., 2008). Future studies should evaluate reasons for this discrepancy and probe potential mechanisms for ROS sensitivity or protection in dLRRK KOs.

**Drosophila Transgenic LRRK2 Models**

As with rodent OE models, Drosophila OE of human LRRK2 G2019S and R1441C has resulted in DA neuronal loss, disruptions of dopamine homeostasis, and L-DOPA responsive locomotor defects (Table 8). Interestingly, other variants such as I1122V, Y1699C, I2020T, and G2385R have also been shown to cause DA neuronal loss in Drosophila (Imai et al., 2008; Liu et al., 2008; Ng et al., 2009; Venderova et al., 2009; Lin et al., 2010; Godena et al., 2014). This loss occurs at mid- to older age (35–60 days) and is commonly seen in the PPL1 DA neuronal cluster (Imai et al., 2008; Liu et al., 2008; Ng et al., 2009; Venderova et al., 2009). In addition to cell loss, transgenic models also exhibit decreased DA content and reduced climbing ability starting at birth or at 10 days, respectively (Imai et al., 2008; Ng et al., 2009). Several studies have also reported sensitivity to ROS in flies expressing pathogenic LRRK2 mutations (Imai et al., 2008; Ng et al., 2009).

Unlike rodent models, OE of human WT LRRK2 has also been reported to induce DA neurodegeneration (Liu et al., 2008). In addition, OE of Drosophila WT dLRRK (under a TH promoter) has also been shown to cause neurodegeneration (Imai et al., 2008). These models raise several questions, including whether DA neuronal loss may be caused by expression of a different species’ LRRK2 and whether cell-type specific expression can cause DA neuronal loss.

**Caenorhabditis elegans LRRK2 MODELS**

Caenorhabditis elegans have a well-characterized CNS with a total of 302 neurons, 8 of which are dopaminergic. Unlike rodents, the simplicity of the C. elegans’s nervous system has allowed for quantification and visualization of DA neuron morphology in vivo (Yao et al., 2010). In addition, its shorter lifespan, small size and cost-effectiveness have facilitated high-throughput drug screening (Maulik et al., 2017). Like Drosophila, C. elegans has one single ortholog of LRRK2, Lrk-1, which is broadly expressed in head and tail neurons, the hypodermis, intestine, and muscles (Sakaguchi-Nakashima et al., 2007). Both Lrk-1 KO and transgenic OE models of LRRK2 have been reported in C. elegans.

**C. elegans Lrk-1 KO Models**

Like other LRRK2 KO models, loss of Lrk-1 does not lead to the degeneration of DA neurons or striking locomotor phenotypes (Sakaguchi-Nakashima et al., 2007; Saha et al., 2009; Sämann et al., 2009; Yao et al., 2010). C. elegans do, however, demonstrate a mis-localization of synaptic vesicles in DA neurons in vivo (Sakaguchi-Nakashima et al., 2007; Sämann et al., 2009). In addition, Lrk-1 KOs have been found to be more sensitive to ER stressors, such as tunicamycin, which has been recently observed to induce the recruitment...
### TABLE 8 | Drosophila transgenic LRRK2 models.

| Author(s), year(s)                          | Model (species, gene, mutation, tag) | DA neuronal loss                                                                 | Locomotor/behavioral changes                                                                 |
|---------------------------------------------|--------------------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|
| **Transgenic overexpression**               |                                      |                                                                                 |                                                                                              |
| **Drosophila models**                       |                                      |                                                                                 |                                                                                              |
| 1 Lin et al., 2010                          | Human *LRRK2* WT – FLAG.              | Not assessed.                                                                   | Not assessed.                                                                                 |
| 2 Lin et al., 2010                          | Human *LRRK2* G2019S – FLAG.          | Loss at 4 weeks in dorsolateral and dorsomedial groups with ddC (dopa decarboxylase) promoter (dopamine and serotonin neuron specific). | Locomotor deficits (climbing index) at 3 weeks and decreased viability at 4 weeks.          |
| 3 Lin et al., 2010; Hindle et al., 2013      | Human *LRRK2* G2385R – FLAG.          | Not assessed.                                                                   | Not assessed.                                                                                 |
| 4 Lin et al., 2010; Hindle et al., 2013; Godena et al., 2014 | Human *LRRK2* R1441C – FLAG | Not assessed.                                                                   | Not assessed.                                                                                 |
| 5 Lin et al., 2010; Hindle et al., 2013      | Human *LRRK2* G2019S-K1906M–FLAG.     | Loss at 50 days with TH promoter (catecholaminergic cell specific) in PPL1 and PPM1/2 neuronal clusters. | Decreased locomotion starting at 10 days (time required to recover from tapping).          |
| 6 Venderova et al., 2009                    | Human *LRRK2* WT.                     | Loss at 50 days with TH promoter in PPL1 and PPM1/2 neuronal clusters.          | Decreased locomotion starting at 10 days (time required to recover from tapping).          |
| 7 Venderova et al., 2009; Hindle et al., 2013 | Human *LRRK2* I1122V.               | Loss at 50 days with TH promoter in PPL1 and PPM1/2 neuronal clusters.          | Decreased locomotion starting at 10 days (time required to recover from tapping).          |
| 8 Venderova et al., 2009                    | Human *LRRK2* Y1699C.                 | Loss at 50 days with TH promoter in PPL1 and PPM1/2 neuronal clusters.          | Decreased locomotion starting at 10 days (time required to recover from tapping).          |
| 9 Venderova et al., 2009; Hindle et al., 2013 | Human *LRRK2* I2020T.               | Loss at 50 days with TH promoter in PPL1 and PPM1/2 neuronal clusters (most dramatic compared to others). | Decreased locomotion starting at 10 days (time required to recover from tapping).          |
| 10 Ng et al., 2009                           | Human *LRRK2* WT – Myc               | No loss.                                                                        | No climbing deficits.                                                                         |
| 11 Ng et al., 2009                           | Human *LRRK2* G2019S – Myc.           | Loss at 60 days old under ddC promoter.                                        | Climbing is impaired at 60 days with ddC promoter.                                          |
| 12 Ng et al., 2009                           | Human *LRRK2* Y1699C – Myc.           | Loss at 60 days old under ddC promoter.                                        | Climbing is impaired at 60 days with ddC promoter.                                          |
| 13 Ng et al., 2009                           | Human *LRRK2* G2386R – Myc.           | Loss at 60 days old under ddC promoter.                                        | No climbing deficits.                                                                         |
| 14 Liu et al., 2008; Hindle et al., 2013; Godena et al., 2014 | Human *LRRK2* WT – FLAG.            | Loss at 35 days using ddC but 49 days with elav promoter (pan-neuronal) (Liu). | Climbing impaired at 4 weeks with ddC promoter and 6 weeks with elav.                       |

(Continued)
| Author(s), year(s) | Model (species, gene, mutation, tag) | DA neuronal loss | Locomotor/behavioral changes |
|-------------------|-------------------------------------|-----------------|-----------------------------|
| 15 Liu et al., 2008; Hindle et al., 2013; Godena et al., 2014 | Human LRRK2 G2019S – FLAG. | Loss at 35 days using dDC promoter and 35 days with elav promoter (Liu). | Climbing impaired at 4 weeks with dDC promoter and 6 weeks with elav (more severe than human LRRK2 WT OE model) (Liu). |
| 16 Imai et al., 2008; Lee et al., 2010; Hindle et al., 2013 | dLRRK WT. | No loss in PPM1/2, PPL1, and PPM3 (Imai). | Not assessed |
| 17 Imai et al., 2008; Hindle et al., 2013; Godena et al., 2014 | dLRRK Y1383C (corresponding to human Y1699C). | Loss at 60 days old using dDC and elav promoter in PPM1/2 and PPL1 (Imai). | Decreased fertility in females (Imai). |
| 18 Imai et al., 2008; Lee et al., 2010; Hindle et al., 2013 | dLRRK I1915T (corresponding to human I2020T). | Loss at 60 days old using dDC and elav4 promoter in PPM1/2 and PPL1 (Imai). | Decreased fertility in females and climbing deficits in 45-day old flies (Imai). |
| 19 Imai et al., 2008; Lee et al., 2010; Hindle et al., 2013 | dLRRK 3KD (K1781, D1882A, and D1912A) “Triple Kinase Dead”. | No loss in PPM1/2, PPL1, and PPM3 (Imai). | No climbing deficits (Imai). |
| 20 Lee et al., 2007 | dLRRK WT – FLAG. | No loss. | No deficits. |
| 21 Lee et al., 2007; Godena et al., 2014 | dLRRK R1069C (corresponding to R1441C). | No loss (Lee). | No deficits. |
of LRRK2 from the trans-Golgi to the lysosome in a Rab29-dependent manner (Sämann et al., 2009; Kuwahara et al., 2016; Eguchi et al., 2018). Both of these processes depend on the phosphorylation of Rab GTPases by LRRK2, and future studies in C. elegans may reveal more mechanistic insight in vivo.

C. elegans LRRK2 Transgenic Models

The OE of human LRRK2 G2019S and R1441C in C. elegans has been shown to cause DA neurodegeneration, reduced dopamine levels, and locomotor dysfunction (Sämann et al., 2009; Yao et al., 2010; Liu et al., 2011). Interestingly, two conflicting studies suggest that LRRK2-mediated neurodegeneration may depend on either GTPase or kinase activity. One study suggests that OE of human LRRK2 K1347A (a defective GTP binding mutant) does not produce Parkinsonian phenotypes in C. elegans, inferring that GTPase activity is essential for toxicity (Yao et al., 2010), while another indicates that the kinase dead human LRRK2 OE also does not produce loss of DA neurons (Liu et al., 2011). Furthermore, OE of human LRRK2 WT has also been shown to cause DA neurodegeneration (Yao et al., 2010). Future C. elegans transgenic OE models will have to clarify these discrepancies and use better GTPase inactive mutants in C. elegans to assess for toxicity.

ZEBRAFISH LRRK2 MODELS

Zebrafish (Danio rerio) is an attractive model due to its well-characterized neuronal circuitry, conserved neurobiochemical mechanisms between humans, optical transparency, small size, and ease of drug administration (Vaz et al., 2018). The lifespan of zebrafish is relatively long compared to other rodent models, with 71% survivability at 5 years, making it ideal for aging research (Vaz et al., 2018). Like Drosophila and C. elegans, zebrafish possess a sole ortholog to human LRRK2, called zLRRK2, sharing a 47% amino acid sequence identity with humans (Sheng et al., 2010).

Zebrafish zLRRK2 KD Models

Since an initial study reported that zLRRK2 KO is embryonically lethal, a targeted knock-down (KD) approach has been used as an alternative to reduce the expression of zLRRK2 (Sheng et al., 2010). This initial study saw that targeting the WD40 domain of zLRRK2 using morpholino oligonucleotides resulted in the loss of diencephalon DA neurons and locomotor defects (Sheng et al., 2010). A later study supported this finding and also observed α-synuclein aggregates in multiple brain regions (Prabhudesai et al., 2016). However, one study using a dosage of morpholinos in between these two studies achieved a greater KD of zLRRK2, but could not replicate these phenotypes (Ren et al., 2011). These studies may show conflicting results due to the reported off-target effects of morpholinos, and thus different approaches should be considered (Kok et al., 2015). As such, further study is required to establish a consistent theme in zebrafish zLRRK2 KD models.

Zebrafish LRRK2 Mutant Models

Limited zebrafish mutant models have been developed, but a recent report using zinc finger nucleases (ZFNs) was able to introduce a mutation in the WD40 domain of zLRRK2 to generate a KI model (Sheng et al., 2018). They observed increases in locomotion in the adult stage and a weakened antibacterial response. Another report using transient overexpression of human LRRK2 WT and G2019S in zebrafish embryos was able to see disruptions in the ubiquitin-proteasome system (UPS) (Lichtenberg et al., 2011). Future studies will have to develop more mutant models of zebrafish models in order to gain more phenotypic insights.

CONCLUDING REMARKS AND FUTURE PERSPECTIVES

Here we highlight several phenotypic themes found in LRRK2-associated PD animal models, with an emphasis on rodents. LRRK2 KO models in mice, rats, Drosophila, and C. elegans have not produced DA neurodegeneration. Rather, phenotypic changes have been observed primarily in peripheral tissues such as the kidneys and lungs. Interestingly, primates treated with LRRK2 kinase inhibitors have also show disruptions in the kidneys and lungs with no obvious neuropathological changes (Fuji et al., 2015). Future models should work to uncover other novel phenotypes associated with LRRK2 KO models, which can be indicative of LRRK2 kinase inhibitor treatment, thereby facilitating the investigation of drug-based toxicity or efficacy. By contrast, transgenic OE of pathogenic LRRK2 in mice and Drosophila has been shown to cause robust DA neurodegeneration, tau and α-synuclein pathology, locomotor/behavioral deficits, alterations in DA homeostasis, and L-DOPA-responsive behavior. A recently reported mouse model was found to have many of these features including DA neurodegeneration, locomotor changes and α-synuclein pathology, and it may be useful for determining drug efficacy (Xiong et al., 2018). Other phenotypes, such as tau pathology and cognitive, behavioral, and peripheral organ changes have not been assessed in this model and could provide other important clinical measures. Finally, LRRK2 KI models used in mice and zebrafish have produced neurophysiological changes and modest behavioral or locomotor abnormalities. These phenotypes seen can be indicative of early or prodromal PD, and with careful behavioral analysis, such as one done by Giesert et al. (2017) in a R1441C KI mouse model, it can reveal other important phenotypes.

An emerging area in LRRK2 biology that may help guide future LRRK2 models is the role of Rab proteins and whether they can be used as an in vivo biomarker for LRRK2 activity. LRRK2 is capable of phosphorylating Rab3A/B/C/D, Rab8A/B, Rab10, Rab12, Rab29, Rab35, and Rab43 (Steger et al., 2016, 2017). Using LRRK2 G2019S, R1441C, kinase-dead, and phosphomimetic (S910A + S935A) KI rodent models, the endogenous phosphorylation of Rab proteins can be carefully evaluated in a tissue-specific manner. This should provide
important clues for cell-type and region-specific readouts of LRRK2 activity (Ito et al., 2016; Lis et al., 2018). Furthermore, a recent study has highlighted LRRK2’s role at the lysosome, where LRRK2 is recruited onto stressed lysosomes by Rab29 and phosphorylates Rab8A and Rab10 (Eguchi et al., 2018). Interestingly, Rab8A KO mice have been developed, which may give important insights into LRRK2 biology at the lysosome (Sato et al., 2007). Furthermore, Rab29 was also observed to be a risk factor for the development of PD, and future studies should investigate a potential unifying mechanism for LRRK2 and Rab29 in PD pathogenesis (MacLeod et al., 2013; Belina et al., 2014; Nalls et al., 2019).

Another emerging area in LRRK2 animal models is the role of LRRK2 in producing immune system abnormalities. A recent LRRK2 phosphomimetic (S910A + S935A) KI mouse model has shown a reduction in astroglisis, while a transgenic OE of LRRK2-G2019S in mice exhibited an increase in astroglisis (Xiong et al., 2018; Zhou et al., 2018). Another study using G2019S KI mice has exhibited astrogliosis using a sub-toxic dose of MPTP dose to cause DA neurodegeneration (Arbez et al., 2019). Investigation of LRRK2 and astrogliosis using these models may help elucidate potential pathogenic mechanisms for LRRK2 in the CNS.

LRRK2 animal models have thus facilitated our understanding of LRRK2 biology, have led us to determine PD pathogenic mechanisms, and have facilitated the discovery of novel phenotypes in LRRK2 pathogenesis in PD and therapeutic development.

AUTHOR CONTRIBUTIONS
SS, GH, and ZY wrote and edited the manuscript. DL had curated information on C. elegans and zebrafish models with assistance from BT. IC and MB provided topic specific knowledge on LRRK2 and guided sections in writing. All authors contributed to the article and approved the submitted version.

FUNDING
This work was supported by an NIH grant (R01NS06123, R01GM115844, and P50NS094733) to ZY. In addition, DL is supported by China Scholarship Council and MB is supported Fundación Ramón Areces.

ACKNOWLEDGMENTS
We would like to thank the Yue lab members for helpful discussions and our colleagues at the Icahn School of Medicine for their support.

REFERENCES
Adams, J. R., Van Netten, H., Schulzer, M., Mak, E., Mckenzie, J., Strongosky, A., et al. (2005). PET in LRRK2 mutations: comparison to sporadic Parkinson’s disease and evidence for presymptomatic compensation. *Brain* 128, 2777–2785. doi: 10.1093/brain/awh660

Andres-Mateos, E., Mejias, R., Sasaki, M., Li, X., Lin, B. M., Biskup, S., et al. (2009). Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). *J. Neurosci.* 29, 15846–15850. doi: 10.1523/JNEUROSCI.4357-09.2009

Arbez, N., He, X., Huang, Y., Ren, M., Liang, Y., Nucifora, F., et al. (2019). G2019S LRRK2 mutation enhances MPTP-linked parkinsonism in mice. *Hum. Molec. Genet.* 29, 580–590. doi: 10.1093/hmg/ddz271

Arranz, A. M., Delbroek, L., Kolen, K., Van Guimara, M. R., Daneels, G., Matta, S., et al. (2015). LRRK2 functions in synaptic vesicle endocytosis through a kinase-dependent mechanism. *J. Cell. Sci.* 128, 541–552. doi: 10.1242/jcs.158196

Bae, E. J., Kim, D. K., Kim, C., Mante, M., Adame, A., Rockenstein, E., et al. (2018). LRRK2 kinase regulates α-synuclein propagation via Rab35 phosphorylation. *Nat. Commun.* 9:18. doi: 10.1038/s41467-018-05998-z

Baptista, M. A. S., Dave, K. D., Frasier, M. A., Sherer, T. B., Greeley, M., Beck, M. J., et al. (2013). Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs. *PLoS One* 8:80705. doi: 10.1371/journal.pone.0080705

Beccano-Kelly, D. A., Kuhnlim, N., Tatarnikov, I., Volta, M., Munsie, L. N., Chou, P., et al. (2014). Synaptic function is modulated by LRRK2 and glutamate release is increased in cortical neurons of G2019S LRRK2 knock-in mice. *Front. Cell. Neurosci.* 8:301. doi: 10.3389/fncel.2014.00301

Beccano-Kelly, D. A., Volta, M., Munsie, L. N., Paschall, S. A., Tatarnikov, I., Kimberly, C., et al. (2015). LRRK2 overexpression alters glutameric presynaptic plasticity, striatal dopamine tone, postsynaptic signal transduction, motor activity and memory. *Hum. Mol. Genet.* 24, 1336–1349. doi: 10.1093/hmg/ddu543

Belina, A., Rudenko, I. N., Kaganovich, A., Civiero, L., Chau, H., Kallia, S. K., et al. (2014). Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial parkinson disease. *Proc. Natl. Acad. Sci. U.S.A.* 111, 2626–2631. doi: 10.1073/pnas.1318306111

Berwick, D. C., Heaton, G. R., Azegagh, S., and Harvey, K. (2019). LRRK2 Biology from structure to dysfunction: research progresses, but the themes remain the same. *Mol. Neurodegener.* 14, 1–22. doi: 10.1186/s13024-019-0344-2

Bichler, Z., Lim, H. C., Zeng, L., and Tan, E. K. (2013). Non-motor and motor features in LRRK2 transgenic mice. *PLoS One* 8:e70249. doi: 10.1371/journal.pone.0070249

Biskup, S., Moore, D. J., Rea, A., Lorenz-Deperieux, B., Coombes, C. E., Dawson, V., et al. (2007). Dynamic and redundant regulation of LRRK2 and LRRK1 expression. *BMC Neurosci.* 8:102. doi: 10.1186/1471-2202-8-102

Boddu, R., Hull, T. D., Bolisetty, S., Hu, X., Moehle, M. S., Daher, J. P. L., et al. (2015). Leucine-rich repeat kinase 2 deficiency is protective in rhabdomyolysis-induced kidney injury. *Hum. Mol. Genet.* 24, 4078–4093. doi: 10.1093/hmg/ddv147

Bosgraaf, L., and Van Haastert, P. J. M. (2003). Roc, a Ras/GTPase domain in complex proteins. *Biochim. Biophys. Acta Mol. Cell. Res.* 1643, 5–10. doi: 10.1016/j.bbamcr.2003.08.008

Burke, R. E., and O’Malley, K. (2013). Axon degeneration in Parkinson’s disease. *Exp. Neurol.* 246, 72–83. doi: 10.1016/j.expneurol.2012.01.011

Chen, C. Y., Weng, Y. H., Chien, K. Y., Lin, K. I., Yeh, T. H., Cheng, Y. P., et al. (2012). (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD. *Cell Death Differ.* 19, 1623–1633. doi: 10.1038/cdd.2012.42

Chen, M. L., and Wu, R. M. (2018). LRRK2 gene mutations in the pathophysiology of the ROCO domain and therapeutic targets for Parkinson’s disease: a review. *J. Biomed. Sci.* 25, 1–11. doi: 10.1186/s12929-018-0454-0

Chou, J. S., Chen, C. Y., Chen, Y. L., Weng, Y. H., Yeh, T. H., Lu, C. S., et al. (2014). (G2019S) LRRK2 causes early-phase dysfunction of SNpc dopaminergic neurons and impairment of corticostriatal long-term depression in the PD transgenic mouse. *Neurobiol. Dis.* 68, 190–199. doi: 10.1016/j.nbd.2014.04.021

Civiero, L., Vancraenenbroeck, R., Belluzzi, E., Belina, A., Lobbestael, E., Reyiners, L., et al. (2012). Biochemical characterization of highly purified leucine-rich repeat kinases 1 and 2 demonstrates formation of homodimers. *PLoS One* 7:43472. doi: 10.1371/journal.pone.0043472
Dächsel, J. C., Behrouz, B., Yue, M., Bevers, J. E., Melrose, H. L., and Farrer, M. J. (2010). A comparative study of Lrrk2 function in primary neuronal cultures. Parkinsonism Relat. Disord. 16, 650–655. doi: 10.1016/j.parkreldis.2010.08.018

Daher, J. P. L., Abdelmotilib, H. A., Hu, X., Volpicelli-Daley, L. A., Moehle, M. S., and Fraser, K. B. (2015). Leucine-rich repeat kinase 2 (LRRK2) pharmacological inhibition ablates α-synuclein gene-induced neurodegeneration. J. Biol. Chem. 290, 19433–19444. doi: 10.1074/jbc.M115.660001

Daher, J. P. L., Volpicelli-Daley, L. A., Blackburn, J. P., Moehle, M. S., and West, A. B. (2014). Abrogation of a-synuclein—mediated dopaminergic neurodegeneration in LRRK2-deficient rats. Proc. Natl. Acad. Sci. U.S.A. 111, 9289–9294. doi: 10.1073/pnas.1403215111

Dickson, D. W., Braak, H., Duda, J. E., Duyskaerts, C., Gasser, T., Halliday, G. M., et al. (2006). Parkinson’s disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinics. Mov. Disord. 21, 519–523. doi: 10.1002/mds.20751

Khan, N. L., Jain, S., Lynch, J. M., Pavese, N., Abou-Sleiman, P., Holton, J. L., et al. (2005). Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson’s disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 128, 2786–2796. doi: 10.1093/brain/avh667

Kuss, J. H., Mamais, A., and Cookson, M. R. (2019). LRRK2 links genetic and sporadic Parkinson’s disease. Biochem. Soc. Trans. 47, 651–661. doi: 10.1042/BST20180462

Kok, F. O., Shin, M., Ni, C. W., Gupta, A., Grosse, A. S., van Impel, A., et al. (2015). Reverse genetic screening reveals poor correlation between morpholinoo-induced mutant phenotypes in zebrafish. Dev. Cell. 32, 97–108. doi: 10.1016/j.devcel.2014.11.018

Lee, J. W., Tapias, V., Di Maio, R., Greenamyre, J. T., and Cannon, J. R. (2015). LRRK2 and RAB7L1 coordinately regulate axonal morphology and lysosome integrity in diverse cellular contexts. Sci. Rep. 5:22945. doi: 10.1038/srep22945

Langston, R. G., Rudenko, I. N., and Cookson, M. R. (2016). The function of orthologues of the human Parkinson’s disease gene LRRK2 across species: implications for disease modelling in preclinical research. Biochem. J. 473, 211–232. doi: 10.1042/BJ20160985

Lee, S., Liu, H. P., Lin, W. Y., Guo, H., and Lu, B. (2010). LRRK2 kinase regulates synaptic morphology through distinct substrates at the presynaptic and postsynaptic compartments of the Drosophila neuromuscular junction. J. Neurosci. 30, 16939–16969. doi: 10.1523/JNEUROSCI.1807-10.2010

Lee, S. B., Kim, W., Lee, S., and Chung, J. (2007). Loss of LRRK2/PARK8 induces degeneration of dopaminergic neurons in Drosophila. Biochem. Biophys. Res. Commun. 358, 534–539. doi: 10.1016/j.bbrc.2007.04.156

Lee, J. W., Tapias, V., Di Maio, R., Greenamyre, J. T., and Cannon, J. R. (2015). Behavioral, neurochemical, and pathogenic alterations in bacterial artificial chromosomes transgenic G2019S leucine-rich repeated kinase 2 rats. Neurobiol. Aging 36, 505–518. doi: 10.1016/j.neurobiolaging.2014.07.011

Lees, A. J., Hardy, J., and Revesz, T. (2009). Parkinson’s disease. Lancet 373, 2055–2066. doi: 10.1016/S0140-6736(09)60492-X

Lesage, S., and Brice, A. (2009). Parkinson’s disease: from monogenic forms to genetic susceptibility factors. Hum. Mol. Genet. 18, 48–59. doi: 10.1093/hmg/ddp012

Lesage, S., Janin, S., Lohmann, E., Leutenegger, A. L., Leclere, L., Viallet, F., et al. (2007). LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans. Arch. Neurol. 64, 425–430. doi: 10.1001/archneur.64.4.425

Li, X., Nicholson, C., Yue, Z., Rice, M. E., Avshalumov, M. V., Patel, J. C., et al. (2010). Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson’s disease gene mutation G2019S. J. Neurosci. 30, 1788–1797. doi: 10.1523/JNEUROSCI.5604-09.2010

Li, X., Tan, Y. C., Poulsou, S., Olanow, C. W., Huang, X. Y., and Yue, Z. (2007). Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possess GTPase activity that is
altered in familial Parkinson's disease R1441C/G mutants. J. Neurochem. 103, 238–247. doi: 10.1111/j.1471-4159.2007.04743.x

Li, Y., Liu, W., Oo, T. F., Wang, L., Tang, Y., Jackson-Lewis, V., et al. (2009). Mutant LRRK2R1441G BAC transgenic mice recapitulate cardinal features of Parkinson's Disease. Nat. Neurosci. Brief. Commun. 12, 826–828. doi: 10.1038/nn.2349

Lichtenberg, M., Mansilla, A., Zecchini, V. R., Fleming, A., and Rubinsztein, D. C. (2011). The Parkinson's disease protein LRRK2 impairs proteasome substrate clearance without affecting proteasome catalytic activity. Cell Death Dis. 2, 1–12. doi: 10.1038/cddis.2011.81

Lim, J., Bang, Y., Choi, J. H., Han, A., Kwon, M. S., Liu, K. H., et al. (2018). LRRK2 G2019S induces anxiety/depression-like behavior before the onset of motor dysfunction with 5-HT 1A receptor upregulation in mice. J. Neurosci. 38, 1611–1621. doi: 10.1523/JNEUROSCI.4051-15.2017

Lin, C. H., Tsai, P. I., Wu, R. M., and Chien, C. T. (2010). LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting a novel caspase-3 activating molecule. J. Neurosci. 30, 13138–13149. doi: 10.1523/JNEUROSCI.1737-10.2010

Lin, X., Parisiadou, L., Gu, X. L., Wang, L., Shim, H., Sun, L., et al. (2009). Leucine-Rich repeat kinase 2 regulates the progression of neuroprotection induced by parkinson’s-disease-related mutant α-synuclein. Neuron 64, 807–827. doi: 10.1016/j.neuron.2009.11.006

Lis, P., Burel, S., Steger, M., Mann, M., Brown, F., Diez, F., et al. (2018). Surfactant secretion in LRRK2 knock-out rats: changes in lamellar body morphology and rate of exocytosis. PLoS One 9, e89426. doi: 10.1371/journal.pone.0084926

Nalls, M. A., Blauwendraat, C., Vallerga, C. L., Heilbronn, K., Bandres-Caga, S., Chang, D., et al. (2019). Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 18, 1091–1102. doi: 10.1016/S1474-4422(19)30320-5

Nguyen, M., and Krainc, D. (2018). LRRK2 phosphorylation of α-syn mediates synaptic defects in dopaminergic neurons from patients with Parkinson’s disease. Proc. Natl. Acad. Sci. U.S.A. 115, 5576–5581. doi: 10.1073/pnas.1715901115

Nichols, R. J., Dzamko, N., Orr, C. M., Deak, M., Ondracek, A., et al. (2010). 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmid localization. J. Biochem. 430, 393–404. doi: 10.1042/BJ20100483

Pan, P.-Y., Li, X., Wu, Z., Chen, Z., Powell, J., et al. (2017). Parkinson’s disease-associated LRRK2 hyperactive kinase mutant disrupts synaptic vesicle trafficking in ventral midbrain neurons. J. Neurosci. 37, 11366–11376. doi: 10.1523/JNEUROSCI.0996-17.2017

Pan, P. Y., Zhu, Y., Shen, Y., and Yue, Z. (2019). Crosstalk between presynaptic trafficking and autophagy in Parkinson’s disease. Neurobiol. Dis. 122, 64–71. doi: 10.1016/j.nbd.2018.04.020

Parkinson’s disease is a multifactorial disease with a complex genetic background. Several genetic mutations have been identified in genes associated with Parkinson's disease, including LRRK2, which plays a crucial role in motor function. The LRRK2 G2019S mutation, for example, has been associated with an increased risk of Parkinson's disease. Research continues to explore the genetic and environmental factors that contribute to Parkinson's disease and to develop new treatments that can improve patient outcomes.

LRRK2 is a large, multifunctional protein that is involved in a variety of biological processes, including vesicle trafficking, endocytosis, and modulation of PKA activity. In the context of Parkinson's disease, LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity. It is hypothesized that LRRK2 may play a role in the development of presynaptic trafficking and autophagy in Parkinson's disease.

Several studies have investigated the role of LRRK2 in the progression of Parkinson's disease. One study found that LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity. This finding suggests that LRRK2 may be a potential target for the development of new treatments for Parkinson's disease.
Ramonet, D., Daher, J. P. L., Lin, B. M., Stafa, K., Kim, J., Banerjee, R., et al. (2011). Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One 6:18568. doi: 10.1371/journal.pone.0018568

Redgrave, P., Rodriguez, M., Smith, Y., Rodriguez-Oroz, M. C., Lehericy, S., Bergman, H., et al. (2010). Goal-directed and habitual control in the basal ganglia: implications for Parkinson's disease. Nat. Rev. Neurosci. 11, 760–772. doi: 10.1038/nrn2915

Ren, G., Xin, S., Li, S., Zhong, H., and Lin, S. (2011). Disruption of lrrk2 does not cause specific loss of dopaminergic neurons in zebrafish. PLoS One 6:26030. doi: 10.1371/journal.pone.0026030

Rivero-Ríos, P., Romo-Lozano, M., Madero-Pérez, J., Thomas, A. P., Biosa, A., Greggio, E., et al. (2019). The G2019S variant of leucine-rich repeat kinase 2 (LRRK2) alters endolysosomal trafficking by impairing the function of the GTPase RABBA. J. Biol. Chem. 294, 4738–4758. doi: 10.1074/jbc.RA118.005008

Saha, S., Guillely, M. D., Ferree, A., Lanceta, J., Chan, D., Ghosh, J., et al. (2009). LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J. Neurosci. 29, 9210–9218. doi: 10.1523/JNEUROSCI.2281-09.2009

Sakaguchi-Nakashima, A., Meit, J. Y., Jin, Y., Matsumoto, K., and Hisamto, N. (2007). LRK-1, a C. elegans PARK8-related kinase, regulates axonal-dendritic polarity of SV proteins. Curr. Biol. 17, 592–598. doi: 10.1016/j.cub.2007.01.074

Sämann, J., Hegermann, J., von Gromoff, E., Eimer, S., Baumeister, R., and Schmidt, E. (2009). Caenorhabditis elegans LRK-1 and PINK-1 act antagonistically in stress response and neurite outgrowth. J. Biol. Chem. 284, 16142–16149. doi: 10.1074/jbc.M802835200

Sato, T., Mushiake, S., Kato, Y., Sato, K., Sato, M., Takeda, N., et al. (2007). The Rab8 GTPase regulates apical protein localization in intestinal cells. Nature 448, 366–369. doi: 10.1038/nature05929

Schrei, A. M., Chaineau, M., Ruan, W., Lin, S., Barker, P. A., Fon, E. A., et al. (2014b). LRRK2 localizes to endosomes and interacts with clathrin-light chains of the autophagy pathway. J. Neurosci. 34, 4390–4404. doi: 10.1093/hmg/ddp394

Shang, Y., Chen, S., Tu, J., and Xiong, Y. (2015). Transgenic LRRK2 (R1441G) rats—a model for Parkinson disease? PeerJ 3:e945. doi: 10.7717/peerj.945

Sheehan, P., and Yue, Z. (2019). Deregulation of autophagy and vesicle trafficking in Parkinson's disease. Neurosci. Lett. 697, 59–65. doi: 10.1016/j.neulet.2018.04.013

Sheng, D., Qu, D., Kwok, K. H. H., Ng, S. S., Lim, A. Y. M., Aw, S. S., et al. (2010). Deletion of the WD40 domain of LRRK2 in zebrafish causes parkinsonism-like loss of neurons and locomotive defect. PLoS Genet. 6:e1000914. doi: 10.1371/journal.pgen.1000914

Sheng, D., Se, K., Hu, X., Yu, D., Wang, Y., Liu, Q., et al. (2018). Disruption of LRRK2 in Zebrafish leads to hyperactivity and weakened antibacterial response. Biochem. Biophys. Res. Commun. 497, 1104–1109. doi: 10.1016/j.bbrc.2018.02.186

Sheng, Z., Zhang, S., Busto, D., Kleinheinz, T., Le Pichon, C. E., Dominguez, S. L., et al. (2012). Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. Sci. Transl. Med. 4:148. doi: 10.1126/scitranslmed.3004485

Shin, N., Jeong, H., Kwon, J., Heo, H. Y., Kwon, J. J., Yun, H. J., et al. (2008). Leucine-rich repeat kinase 2 interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson's disease. Hum. Mol. Genet. 18, 4390–4404. doi: 10.1093/hmg/ddp394

Volpicelli-Daley, L. A., Abdelmotilib, H., Liu, Z., Stokya, L., Dahr, J. P. L., Milnerwood, A. J., et al. (2016). G2019S-LRRK2 expression augments α-synuclein sequestration into inclusions in neurons. J. Neurosci. 36, 7415–7427. doi: 10.1523/JNEUROSCI.3642-15.2016

Volta, M., Becca–Kelly, D. A., Paschall, S. A., Cataldi, S., Macisaca, S. E., Kuhlmann, N., et al. (2017). Initial elevations in glutamate and dopamine neurotransmission decline with age, as does exploratory behavior, in LRRK2 G2019S knock-in mice. eLife 6:28377. doi: 10.7554/eLife.28377

Volta, M., Cataldi, S., Becca–Kelly, D., Munsie, L., Tartrnikov, I., Chou, P., et al. (2015). Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release. Parkinsonism. Relat. Disord. 21, 1156–1163. doi: 10.1016/j.parkreldis.2015.07.025

Walker, M. D., Volta, M., Cataldi, S., Dinelle, K., Becca–Kelly, D., Munsie, L., et al. (2014). Behavioral deficits and striatal DA signaling in LRRK2 p. G2019S transgenic rats: a multimodal investigation including PET neuroimaging. J. Park. Dis. 4, 483–498. doi: 10.2332/PJPD–140344

Wang, D., Tang, B., Zhao, G., Pan, Q., Xia, K., Bodmer, R., et al. (2008). Dispensable role of Drosophila ortholog of LRRK2 kinase activity in survival of dopaminergic neurons. Mol. Neurodegener. 3:3. doi: 10.1186/1750-1377-3-3

Wang, L., Xie, C., Greggio, E., Parisadou, L., Shim, H., Sun, L., et al. (2008). The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J. Neurosci. 28, 3384–3391. doi: 10.1523/JNEUROSCI.0815-08.2008

Weng, Y. H., Chen, C. Y., Lin, K. J., Chen, Y. L., Hsiao, I. T., et al. (2016). (R1441C) LRRK2 induces the degeneration of SN dopaminergic neurons and alters the expression of genes regulating neuronal survival in a transgenic mouse model. Exp. Neurobiol. 25, 104–115. doi: 10.5501/ExpN.2015.09001

West, A. B., Cowell, R. M., Daher, J. P. L., Moeleh, M. S., Hinkle, K. M., Melrose, H. L., et al. (2014). Differential LRRK2 expression in the cortex, striatum, and...
substantia nigra in transgenic and nontransgenic rodents. J. Comp. Neurol. 522, 2465–2480. doi: 10.1002/cne.23583

West, A. B., Moore, D. J., Biskup, S., Bugayenko, A., Smith, W. W., Ross, C. A., et al. (2005). Parkinson’s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. U.S.A. 102, 16842–16847. doi: 10.1073/pnas.0507360102

Xing, W., Goodluck, H., Zeng, C., and Mohan, S. (2017). Role and mechanism of action of leucine-rich repeat kinase 1 in bone. Bone Res. 5:17003. doi: 10.1038/boneres.2017.3

Xiong, Y., Neifert, S., Karuppagounder, S. S., Liu, Q., Stankowski, J. N., Lee, B. D., et al. (2018). Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 115, 1635–1640. doi: 10.1073/pnas.1712648115

Yao, C., El Khoury, R., Wang, W., Byrd, T. A., Pehek, E. A., Thacker, C., et al. (2010). LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson’s disease. Neurobiol. Dis. 40, 73–81. doi: 10.1016/j.nbd.2010.04.002

Yue, M., Hinkle, K. M., Davies, P., Trushina, E., Fiesel, F. C., Christenson, T. A., et al. (2015). Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice. Neurobiol. Dis. 78, 172–195. doi: 10.1016/j.nbd.2015.02.031

Zhou, H., Huang, C., Tong, J., Hong, W. C., Liu, Y. J., and Xia, X. G. (2011). Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake. Int. J. Biol. Sci. 7, 753–761. doi: 10.7150/ijbs.7.753

Zhou, H., Huang, C., Yang, M., Landel, C. P., Xia, P. Y., Liu, Y. J., et al. (2009). Developing tTA transgenic rats for inducible and reversible gene expression. Int. J. Biol. Sci. 5, 171–181. doi: 10.7150/ijbs.5.171

Zhou, Y., Keshiya, S., Atashrazm, F., Gao, J., Ittner, L. M., Allesi, D. R., et al. (2018). Nigrostriatal pathology with reduced astrocytes in LRRK2 S910/S935 phosphorylation deficient knockin mice. Neurobiol. Dis. 120, 76–87. doi: 10.1016/j.nbd.2018.09.003

Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., et al. (2004). Mutations in LRRK2 cause autosomal-dominant parkinsonism with plemorphic pathology. Neuron 44, 601–607.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The handling Editor HR declared a past co-authorship with the author ZY.

Copyright © 2020 Seegobin, Heaton, Liang, Choi, Blanca Ramirez, Tang and Yue. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.